Arsenal deliver fitness update on Laurent Koscielny and Granit Xhaka ahead of Napoli clash

first_img Comment Advertisement Metro Sport ReporterWednesday 10 Apr 2019 10:27 amShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link Arsenal deliver fitness update on Laurent Koscielny and Granit Xhaka ahead of Napoli clashcenter_img Arsenal are hoping to have Laurent Koscielny and Granit Xhaka available for Thursday’s game against Napoli (Getty Images)Arsenal captain Laurent Koscielny and midfielder Granit Xhaka are both being assessed by the club ahead of the Europa League quarter-final first leg against Napoli on Thursday.Koscielny has endured a stop-start campaign having missed the first three months of the season after rupturing his Achilles in May and has been absent since last month’s win against Rennes due to a foot problem.Xhaka, meanwhile, had been a mainstay of Unai Emery’s side until suffering a groin strain at the end of January and aggravating the problem last month. Neither player was available for Sunday’s disappointing 1-0 defeat to Everton at Goodison Park.AdvertisementAdvertisementAfter that game, Emery said: “Maybe Laurent could’ve come back to play today but yesterday we knew it wasn’t possible. I want to be positive for Thursday but it depends how he’s progressing. Xhaka is the same. They are doubts for Thursday.’ADVERTISEMENTMore: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man CityEmery will be hoping to have both players available for the visit of Carlo Ancelotti’s Napoli side in order to maximise Arsenal’s chances of getting a positive result at the Emirates prior to the return leg in Naples next week. Arsenal have lost both of their away knockout games in the Europa League this term.Should Xhaka be deemed fit enough to be involved on Thursday night, he is one of three Arsenal players at risk of suspension for the second leg having picked up three yellow cards during the competition. He along with Henrikh Mkhitaryan and Sokratis Papastathopolous are all one booking away from a suspension.Emery has virtually a full squad to pick from otherwise although Hector Bellerin, Danny Welbeck and Rob Holding all remain long-term absentees.More: Arsenal FCArsenal flop Denis Suarez delivers verdict on Thomas Partey and Lucas Torreira movesThomas Partey debut? Ian Wright picks his Arsenal starting XI vs Manchester CityArsene Wenger explains why Mikel Arteta is ‘lucky’ to be managing Arsenal Advertisementlast_img read more

Freeze warning in effect overnight

first_imgDecatur, Franklin, and Ripley Counties, IN— The National Weather Service has issued a Freeze Warning overnight from 1 am to 9 am on Wednesday for all of southeastern Indiana.  Temperatures will reach below 30 degrees overnight and in the early morning.  Frost and freeze conditions will kill crops, other sensitive vegetation and possibly damage unprotected outdoor plumbing. They advise you to take steps now to protect tender plants from the cold. To prevent freezing and possible bursting of outdoor water pipes they should be wrapped, drained, or allowed to drip slowly. Those that have in-ground sprinkler systems should drain them and cover above-ground pipes to protect them from freezing.last_img read more

Women’s AFCON: Super Falcons Draw S’Africa, Zambia, Kenya

first_imgThe final tournament is scheduled for the Ghanaian cities of Accra and Cape Coast from 17 November to 1 December 2018. The top three finishers will qualify to represent Africa at the FIFA Women’s World Cup France 2018.Before the Draw, Zambia had planed to set up training camp in Nigeria and were in the process of arranging friendlies with some top Nigerian female teams in the Nigerian Women’s Football League.Meanwhile, the Super Falcons star, Asisat Oshoala and her teammates retained the Chinese Women Super League title at the weekend.Oshoala starred as her Dalian Quanjian side retained the Chinese Women Super League title after a 0-0 draw with Jiangsu Suning Dalian Sports Center, Liaoning on Saturday.Prior to the encounter, the champions needed a draw, while their second-placed visitors, who have Malawian Tabitha Chawinga in their books, were chasing a win to close the gap with the hosts.On the match day, both sides were impressive with a fair share of chances in the desperate battle to claim the diadem, the hosts held their nerve to avoid a home defeat.After the stalemate, Dalian now have 32 points – four above Jiangsu on 28 to officially emerge as the Chinese women’s topflight league champions with a game to spare.The former Arsenal Ladies contributed ten goals this season to help Dalian to a title win and also make a huge statement for 2018 Africa Women’s Cup of Nations in Ghana.And the reigning African Women’s Player of the Year, has taken to social media to celebrate her back-to-back league title success in China.Having emerged 2018 champions, Oshoala and Dalian would wrap up their league campaign against third-placed Changchun in a dead rubber encounter on October 27, 2018.Share this:FacebookRedditTwitterPrintPinterestEmailWhatsAppSkypeLinkedInTumblrPocketTelegram By Duro IkhazuagbeNigeria’s Super Falcons who are defending champions of the Women’s Africa Cup of Nations have been drawn with South Africa, Zambia and Kenya in Group B of the 2018 edition scheduled to hold next month in Ghana.Falcons will begin the defence of the trophy they won in Cameroon next month in Cape Coast.In the Draw conducted at the Movenpick Ambassador Hotel in Accra last night, the host country Ghana was paired along with Cameroon, Algeria and Mali in Group A.Both Nigeria and Ghana were the top seeds at the draw ceremony conducted by CAF’s Deputy Secretary General, Anthony         Baffoe and a host of former Black Queens players including Adjoa Bayor and Memunatu Sulemana.last_img read more

Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers

first_imgA tiny San Diego-based company provided an experimental Ebola treatment for two Americans infected with the deadly virus in Liberia. The biotechnology drug, produced with tobacco plants, appears to be working.In an unusual twist of expedited drug access, Mapp Biopharmaceutical Inc., which has nine employees, released its experimental ZMapp drug, until now only tested on infected animals, for the two health workers. Kentucky BioProcessing LLC, a subsidiary of tobacco giant Reynolds American Inc. (RAI), manufactures the treatment for Mapp from tobacco plants.The first patient, Kent Brantly, a doctor, was flown from Liberia to Atlanta on Aug. 2, and is receiving treatment at Emory University Hospital. Nancy Writebol, an aid worker, is scheduled to arrive in Atlanta today and will be treated at the same hospital, according to the charity group she works with. Both are improving, according to relatives and supporters.Each patient received at least one dose of ZMapp in Liberia before coming to the U.S., according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.“There’s a very scarce number of doses,” and it’s not clear how many each patient needs for treatment, Fauci said. “I’m not sure how many doses they’ll get.”Citing unnamed sources, CNN yesterday reported that the drug used for the treatment is Mapp’s.Ebola, spread through direct contact with body fluids such as blood and urine, has sickened 1,603 people in West Africa, killing 887, according to the World Health Organization. The disease, first reported in what is now the Democratic Republic of Congo in 1976, can cause bleeding from the eyes, ears and nose.http://www.bloomberg.com/quicktake/ebola/The virus has historically killed as many as 90 percent of those who contract it. The current outbreak has a fatality rate of about 60 percent, probably because of early treatment efforts, officials have said.There is no cure for Ebola, although several companies — including Mapp — are working on drug candidates that are undergoing animal testing. Normally, patients are given fluids, blood transfusions and antibiotics with the hope their immune systems can fight off Ebola’s onslaught.The two scientists behind Mapp, President Larry Zeitlin and Chief Executive Officer Kevin Whaley, “are both brilliant,” said Charles Arntzen, a plant biotechnology expert at Arizona State University who collaborated with the two researchers years ago. “They are very, very bright guys and free spirits.”The antibody work came out of research projects funded more than a decade ago by the U.S. Army to develop treatments and vaccines against potential bio-warfare agents, such as the Ebola virus, Arntzen said in a telephone interview.Tobacco PlantThe tobacco plant production system was developed because it was a method that could produce antibodies rapidly in the event of an emergency, he said.To produce therapeutic proteins inside a tobacco plant, genes for the desired antibodies are fused to genes for a natural tobacco virus, said Arntzen. The tobacco plants are then infected with this new artificial virus, he said.“The infection results in the production of antibodies inside the plant,” Arntzen said. The plant is eventually ground up and the antibody is extracted, he said. The whole process takes a matter of weeks.When confronted by reporters about the Ebola infections in Liberia and subsequent treatments, Whaley said he needed to get up to speed on the developing events.“This is all new to me,” said Whaley, who was dressed in shorts, a well-worn T-shirt and flip-flops while addressing reporters’ questions outside the company’s offices in a San Diego business park. “I just don’t want to give out any inaccurate information, that’s all.”Antibody CocktailMapp’s drug is being developed with Toronto-based Defyrus Inc., which has six employees, according to Defyrus CEO Jeff Turner. ZMapp is a “cocktail” of monoclonal antibodies that help the immune system attack the virus.Monoclonal antibodies designed to fight and block specific proteins can stop the virus from latching onto and entering cells, said Heinz Feldmann, chief of the National Institute of Allergy and Infectious Diseases’ Laboratory of Virology in Hamilton, Montana.The key is to find antibodies that can prevent viral infection, and to attack several points on the virus so that mutants won’t “escape” treatment, he said.“What you want is a cocktail of antibodies that target different domains on the virus so escape is less likely in treatment,” he said in a telephone interview. Feldmann said he hasn’t been involved in developing treatments.ZMapp’s predecessor, MB-003, protected three of seven rhesus macaques in a study run in 2013 by Mapp and the U.S. Army Medical Research Institute of Infectious Diseases.Ethical QuestionsEbola and virology experts believe the use of the Mapp drug for Brantly and Writebol is unusual in the annals of emergency drug treatments. While potentially saving lives, the cases raise questions about who should have the right to receive experimental drugs years before they gain FDA approval.“There are a lot of Africans that are also dying,” Robert Garry, a virologist at Tulane University, said in a telephone interview. “If we are going to do it for the Americans then we should certainly step up our game for the Africans.”Although no drugs to treat Ebola are approved by U.S. regulators, the Food and Drug Administration can approve an emergency application to provide access to unapproved drugs, Stephanie Yao, an FDA spokeswoman, said in an e-mail.Emergency ApprovalApproval for emergency drug use outside of a clinical trial can be made within 24 hours, Yao wrote. Shipment and treatment with the drug could begin even before completed written forms are submitted to the FDA, which can approve the use of an experimental treatment by telephone in an emergency.“The FDA stands ready to work with companies and investigators treating these patients who are in dire need of treatment,” Yao said. She declined to say whether the FDA had allowed any drug to be used in the Ebola outbreak.Erica Ollmann Saphire, a molecular biologist at the Scripps Research Institute in San Diego, worked with Mapp and the other biotechnology companies to develop models of the Ebola virus and potential antibodies.She directs a global consortium given the job of modeling the virus and the mixture of antibodies needed to defeat it. She said the drug was approved for the two American medical workers in Liberia under a compassionate-use doctrine, because it’s not even scheduled for clinical trials until next year.Informed Consent“I’d take it myself,” she said in an interview in her laboratory, near La Jolla. “Absolutely. I wouldn’t think twice.”She said the American medical aid workers were in a better position to give consent to the treatment than African disease victims.“Do you put an untested therapy in a human or do you just watch them die?” Saphire asked. “Certainly these two Americans are medically trained individuals who knew what they were getting into. They are able to give informed consent.”Medical care of the two U.S. citizens may take two to three weeks if all goes well, Bruce Ribner, an infectious disease specialist at Emory, said in an Aug. 1 news conference.The Atlanta-based Centers for Disease Control and Prevention, which confirmed that Brantly and Writebol are the first Ebola patients on U.S. soil, is working with the hospital and transport company to make sure evacuation of the two patients goes safely, said Barbara Reynolds, an agency spokeswoman.“We’re here to make sure the transportation process and the care here in the U.S. ensures there’s no spread,” Reynolds said. “It’s important to remember this is not an airborne virus, it requires close contact with body fluids. It’s minimal risk as long as the people caring for the patient use meticulous procedures.”To contact the reporters on this story: Robert Langreth in New York at rlangreth@bloomberg.net; Caroline Chen in New York at cchen509@bloomberg.net; John Lauerman in Boston at jlauerman@bloomberg.netShare this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)last_img read more